<html><head></head><body><h1>Calaspargase Pegol-mknl</h1><p class="drug-subtitle"><b>Class:</b> Antineoplastic Agents<br/>
<b>Chemical Name:</b> [27-Alanine,64-aspartic acid,252-threonine,263-asparagine]-L-asparaginase 2 (EC 3.5.1.1, L-asparagine amidohydrolase II) Escherichia coli (strain K12) tetramer α4, carbamates with α-carboxy-ω-methoxypoly(oxyethylene)<br/>
<b>Molecular Formula:</b> C<sub>1516</sub>H<sub>2423</sub>N<sub>415</sub>O<sub>492</sub>S<sub>8</sub><br/>
<b>CAS Number:</b> 941577-06-6<br/>
<b>Brands:</b> Asparlas</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li>
<li>FAQ</li></ul><h2>Introduction</h2><p>Antineoplastic agent; conjugate of monomethoxy polyethylene glycol (mPEG) and <i>Escherichia coli</i>-derived asparaginase.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Calaspargase Pegol-mknl</h2><h3>Acute Lymphocytic (Lymphoblastic) Leukemia (ALL)</h3><p>Component of combination chemotherapy for treatment of childhood and young adult ALL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Asparaginase preparations used in induction and/or intensification (consolidation) regimens prior to maintenance therapy; CNS-directed therapy (for prophylaxis of CNS involvement) also required.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In childhood ALL, combination therapy with an asparaginase preparation, a corticosteroid (dexamethasone or prednisone), and vincristine, with or without an anthracycline (daunorubicin or doxorubicin), is used as an induction regimen.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Some clinicians reserve 4-drug induction regimens for those with high-risk childhood ALL, while others use such regimens for all patients with childhood ALL regardless of presenting features.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Multiple-drug induction regimens produce complete remission in ≥95% of children with ALL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In adults, induction regimens typically include an anthracycline, vincristine, and prednisone; some regimens also add other drugs (e.g., an asparaginase preparation, cyclophosphamide).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Such induction regimens produce complete remission in about 60–90% of adults with ALL.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adolescents and young adults appear to have better outcomes with use of pediatric-based treatment regimens for ALL instead of traditional adult treatment regimens.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Calaspargase Pegol-mknl Dosage and Administration</h2><h3>General</h3><ul>
<li>
<p>Monitor patients for hypersensitivity reactions for 1 hour after administration of calaspargase pegol; be prepared to provide immediate treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hypersensitivity under Cautions.)</p>
</li>
<li>
<p>Monitor bilirubin, aminotransferase, and glucose concentrations and perform clinical examinations at least weekly until patient recovers from the treatment cycle.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Consult specialized references for procedures for proper handling and disposal of antineoplastics.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;41&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Monitor patients for hypersensitivity reactions for 1 hour after administration of calaspargase pegol; be prepared to provide immediate treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hypersensitivity under Cautions.)</p><p>Monitor bilirubin, aminotransferase, and glucose concentrations and perform clinical examinations at least weekly until patient recovers from the treatment cycle.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Consult specialized references for procedures for proper handling and disposal of antineoplastics.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;41&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>For solution compatibility information, see Compatibility under Stability.</p><p>Administer by IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Injection concentrate must be diluted prior to administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer diluted solution into a running infusion of the same solution (0.9% sodium chloride injection or 5% dextrose injection) used for dilution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Injection concentrate should be clear and colorless.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not use if cloudy or discolored or if particulate matter is present.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also do not use if injection concentrate has been shaken or vigorously agitated, frozen, or stored at room temperature for &gt;48 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Withdraw the calculated dose from the vial and dilute in 100 mL of 0.9% sodium chloride injection or 5% dextrose injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discard any partially used vial.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer by IV infusion over 1 hour.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Dosage expressed in units.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Pediatric patients ≥1 month of age: 2500 units/m<sup>2</sup> no more frequently than every 21 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Consult published protocols for the dosage of calaspargase pegol and other chemotherapeutic agents and the method and sequence of administration.</p><p>If an adverse reaction occurs, modify treatment accordingly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; See Table 1.</p><p>Adverse Reaction and Severity</p><p>Modification</p><p><b>Infusion Reaction or Hypersensitivity Reaction</b></p><p>Grade 1</p><p>Reduce infusion rate by 50%</p><p>Grade 2</p><p>Interrupt therapy and treat symptoms; when symptoms resolve, resume infusion at reduced rate of 50%</p><p>Grade 3 or 4</p><p>Permanently discontinue therapy</p><p><b>Hemorrhage</b></p><p>Grade 3 or 4</p><p>Withhold therapy and evaluate for presence of coagulopathy; consider whether clotting factor replacement is needed; if bleeding is controlled, resume therapy with next scheduled dose</p><p><b>Pancreatitis</b></p><p>Grade 3 or 4</p><p>For lipase or amylase concentrations &gt;3 times the ULN, withhold therapy until enzyme concentrations stabilize or decline; permanently discontinue therapy if pancreatitis is confirmed</p><p><b>Thromboembolism</b></p><p>Uncomplicated DVT</p><p>Withhold therapy and initiate appropriate antithrombotic therapy; when symptoms resolve, may consider resuming therapy while continuing antithrombotic therapy</p><p>Severe or life-threatening thrombosis</p><p>Permanently discontinue therapy and initiate appropriate antithrombotic therapy</p><p><b>Hepatotoxicity</b></p><p>Total bilirubin concentration &gt;3 times to ≤10 times the ULN</p><p>Withhold therapy until total bilirubin concentrations ≤1.5 times the ULN</p><p>Total bilirubin concentration &gt;10 times the ULN</p><p>Discontinue therapy; do not make up for missed doses</p><p>Adults ≤21 years of age: 2500 units/m<sup>2</sup> no more frequently than every 21 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Consult published protocols for the dosage of calaspargase pegol and other chemotherapeutic agents and the method and sequence of administration.</p><p>If an adverse reaction occurs, modify treatment accordingly.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Recommendations for treatment modification for toxicity in pediatric patients also apply to young adults (see Table 1).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Manufacturer recommends administering no more frequently than every 21 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Manufacturer recommends administering no more frequently than every 21 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>Manufacturer makes no specific dosage recommendations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Contraindicated in patients with severe hepatic impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hepatic Impairment under Cautions and also see Metabolism under Pharmacokinetics.)</p><p>Manufacturer makes no specific dosage recommendations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Renal Impairment under Cautions and also see Elimination Route under Pharmacokinetics.)</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Calaspargase Pegol-mknl</h2><h3>Contraindications</h3><ul>
<li>
<p>History of serious hypersensitivity reactions, including anaphylaxis, to pegylated asparaginase.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hypersensitivity under Cautions.)</p>
</li>
<li>
<p>History of serious thrombosis, pancreatitis, or hemorrhagic events during previous therapy with asparaginase.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Severe hepatic impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>History of serious hypersensitivity reactions, including anaphylaxis, to pegylated asparaginase.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hypersensitivity under Cautions.)</p><p>History of serious thrombosis, pancreatitis, or hemorrhagic events during previous therapy with asparaginase.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Severe hepatic impairment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Grade 3 or 4 hypersensitivity reactions, including anaphylaxis, reported with calaspargase pegol therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Other hypersensitivity reactions (e.g., angioedema, lip or eye swelling, erythema, hypotension, bronchospasm, dyspnea, pruritus, rash) also reported with other asparaginase preparations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer calaspargase pegol in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis (e.g., epinephrine, oxygen, IV corticosteroids, antihistamines).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Observe patients for 1 hour following infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If a serious hypersensitivity reaction occurs, discontinue the drug and initiate appropriate therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage under Dosage and Administration.)</p><p>Pancreatitis reported with calaspargase pegol therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Hemorrhagic or necrotizing pancreatitis also reported with other asparaginase preparations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Measure serum amylase and/or lipase concentrations to identify early signs of pancreatic inflammation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If pancreatitis is suspected, withhold calaspargase pegol therapy; if confirmed, permanently discontinue therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage under Dosage and Administration.)</p><p>Serious thrombotic events (e.g., sagittal sinus thrombosis) reported with calaspargase pegol therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discontinue the drug in patients experiencing serious thrombotic events.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage under Dosage and Administration.)</p><p>Hemorrhagic events associated with increased PT, increased PTT, and hypofibrinogenemia reported with calaspargase pegol therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Evaluate coagulation parameters (e.g., PT, PTT, fibrinogen) in patients with signs and symptoms of hemorrhage.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Consider the need for appropriate clotting factor replacement therapy in patients with severe or symptomatic coagulopathy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage under Dosage and Administration.)</p><p>Hepatotoxicity and abnormal liver function, including elevations in aminotransferase and bilirubin (direct and indirect) concentrations and reduced serum albumin and plasma fibrinogen concentrations, can occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor bilirubin and aminotransferase concentrations at least weekly during treatment cycles including calaspargase pegol and for 6 weeks after last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If serious hepatotoxicity occurs, discontinue calaspargase pegol and initiate supportive care.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage under Dosage and Administration.)</p><p>May cause fetal harm based on animal findings.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Studies in pregnant rabbits suggest that asparagine depletion may harm animal offspring.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Confirm pregnancy status prior to initiating calaspargase pegol therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid pregnancy during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Women of childbearing potential should use effective methods of contraception, including a barrier method, while receiving calaspargase pegol and for ≥3 months after last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid concomitant use of oral contraceptives and calaspargase pegol.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Specific Drugs under Interactions.) If used during pregnancy or if patient becomes pregnant, apprise of potential fetal hazard.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Potential for immunogenicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Although development of anti-drug antibodies reported,&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; immunogenic potential of calaspargase pegol-mknl not fully established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May cause fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Fetal/Neonatal Morbidity and Mortality under Cautions.)</p><p>Not known whether calaspargase pegol distributes into human milk or has any effects on milk production or on the nursing infant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Women should not breast-feed during therapy and for ≥3 months after last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy for treatment of ALL in pediatric patients 1 month through 16 years of age supported by evidence from an adequate and well-controlled clinical trial and an additional safety trial in a total of 208 pediatric patients (19 infants, 128 children, 61 adolescents).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; No clinically meaningful differences in safety or serum trough asparaginase activity noted across age groups.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Effects of hepatic impairment on pharmacokinetics not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Contraindications under Cautions.)</p><p>Effects of renal impairment on pharmacokinetics not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Elevated concentrations of aminotransferases and bilirubin, pancreatitis, abnormal clotting studies.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Calaspargase Pegol-mknl</h2><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Oral contraceptives</p><p>Possible indirect interaction (asparaginase-induced hepatotoxicity may impair hepatic clearance of oral contraceptives)&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;41&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid concomitant use&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Calaspargase Pegol-mknl Pharmacokinetics</h2><h3>Absorption</h3><p>Following IV administration of calaspargase pegol-mknl, pharmacokinetics of plasma asparaginase activity are nonlinear.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following IV administration of a single 2500-unit/m<sup>2</sup> dose, peak plasma concentration attained after approximately 1 hour, generally near the end of the 1-hour infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Steady-state concentrations achieved around the fourth dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Rapidly depletes plasma asparagine (i.e., concentrations below the lower limit of quantification within 5 minutes after the dose) in the induction phase.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Plasma asparagine concentrations remained less than the assay limit of quantification for &gt;18 days following a single 2500-unit/m<sup>2</sup> dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Serum trough asparaginase activity of ≥0.1 units/mL correlates with asparagine depletion in CSF and serum; has been established as a surrogate measure of asparaginase efficacy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Steady-state serum trough asparaginase activity for calaspargase pegol-mknl 2500 units/m<sup>2</sup> every 3 weeks comparable to that for pegaspargase 2500 units/m<sup>2</sup> every 2 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Not known whether calaspargase pegol is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Asparaginase does not appear to cross blood-brain barrier; however, CSF asparagine depletion occurs as a result of plasma asparagine depletion following treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Not metabolized by hepatic enzymes; expected to undergo proteolytic degradation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Unlikely to be renally filtered.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Approximately 16 days;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; about 2.5–3 times longer than asparaginase activity half-life of pegaspargase.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>2–8°C; if necessary, may store at 15–25°C for up to 48 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Store in original carton to protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not shake or freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Diluted solution: If immediate use not possible, store at 15–25°C for up to 4 hours or 2–8°C for up to 24 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not shake or freeze.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Compatible</p><p>Dextrose 5% in water</p><p>Sodium chloride 0.9%</p><h2>Actions</h2><ul>
<li>
<p>Depletes the amino acid asparagine, which is required by tumor cells to synthesize protein, RNA, and DNA.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;41&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Breaks down extracellular asparagine into aspartic acid and ammonia, which causes depletion of asparagine and kills leukemic cells.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Longer acting than pegaspargase.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Plasma Concentrations and also Half-life under Pharmacokinetics.) <i>E. coli</i>-derived l-asparaginase is conjugated to mPEG via a succinimidyl carbonate (SC) linker in calaspargase pegol and via a succinimidyl succinate (SS) linker in pegaspargase; the SC linker creates a more stable molecule.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Depletes the amino acid asparagine, which is required by tumor cells to synthesize protein, RNA, and DNA.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;41&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Breaks down extracellular asparagine into aspartic acid and ammonia, which causes depletion of asparagine and kills leukemic cells.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Longer acting than pegaspargase.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Plasma Concentrations and also Half-life under Pharmacokinetics.) <i>E. coli</i>-derived l-asparaginase is conjugated to mPEG via a succinimidyl carbonate (SC) linker in calaspargase pegol and via a succinimidyl succinate (SS) linker in pegaspargase; the SC linker creates a more stable molecule.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Risk of serious allergic reactions, including anaphylaxis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinician immediately if symptoms of serious allergic reactions (e.g., angioedema, lip or eye swelling, hypotension, bronchospasm, dyspnea, rash) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of pancreatitis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinician immediately if severe abdominal pain occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of hyperglycemia and glucose intolerance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinician if excessive thirst or increased urinary volume or frequency occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of thrombosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinician immediately if severe headache, swelling of arms or legs, shortness of breath, or chest pain occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinician if any unusual bleeding or bruising occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinician immediately if jaundice, severe nausea or vomiting, or easy bruising or bleeding occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of women informing clinicians if they are or plan to become pregnant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Necessity of advising women of reproductive potential that they should use effective methods of contraception while receiving the drug and for ≥3 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of advising women that concomitant use of calaspargase pegol and oral contraceptives is not recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of advising women to avoid breast-feeding while receiving calaspargase pegol and for ≥3 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Risk of serious allergic reactions, including anaphylaxis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinician immediately if symptoms of serious allergic reactions (e.g., angioedema, lip or eye swelling, hypotension, bronchospasm, dyspnea, rash) occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of pancreatitis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinician immediately if severe abdominal pain occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of hyperglycemia and glucose intolerance.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinician if excessive thirst or increased urinary volume or frequency occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of thrombosis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinician immediately if severe headache, swelling of arms or legs, shortness of breath, or chest pain occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinician if any unusual bleeding or bruising occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinician immediately if jaundice, severe nausea or vomiting, or easy bruising or bleeding occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of fetal harm.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of women informing clinicians if they are or plan to become pregnant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Necessity of advising women of reproductive potential that they should use effective methods of contraception while receiving the drug and for ≥3 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of advising women that concomitant use of calaspargase pegol and oral contraceptives is not recommended.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of advising women to avoid breast-feeding while receiving calaspargase pegol and for ≥3 months after the last dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Concentrate, for injection, for IV infusion</p><p>750 units/mL</p><p>Asparlas<sup></sup></p><p>Servier</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions April 27, 2020. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><h2>References</h2><p>1. Servier Pharmaceuticals LLC. Asparlas<sup></sup> (calaspargase pegol-mknl) injection prescribing information. Boston, MA; 2019 Sep.</p><p>2. Schore RJ, Devidas M, Bleyer A et al. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. <i>Leuk Lymphoma</i>. 2019; 60:1740-1748. http://www.ncbi.nlm.nih.gov/pubmed/30626253?dopt=AbstractPlus</p><p>3. Li RJ, Jin R, Liu C et al. FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults. <i>Clin Cancer Res</i>. 2019; http://www.ncbi.nlm.nih.gov/pubmed/31444252?dopt=AbstractPlus</p><p>4. Angiolillo AL, Schore RJ, Devidas M et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. <i>J Clin Oncol</i>. 2014; 32:3874-82. http://www.ncbi.nlm.nih.gov/pubmed/25348002?dopt=AbstractPlus</p><p>5. Food and Drug Administration. Center for Drug Evaluation and Research. Application number: 761102Orig1s000: Multi-discipline review. From FDA website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761102Orig1s000MultidisciplineR.pdf</p><p>6. Schore RJ, Devidas M, Bleyer A et al. Anti-pegaspargase, anti-calaspargase pegol, and anti-polyethylene glycol antibody incidence in high risk acute lymphoblastic leukemia patients receiving pegaspargase or calaspargase pegol and associated anaphylactic or hypersensitivity reaction rates: results from the Children's Oncology Group (COG) study AALL07P4. ASH Annual Meeting Abstracts. <i>Blood</i>. 2016; 128:3965. https://ashpublications.org/blood/article/128/22/3965/114223/AntiPegaspargase-AntiCalaspargase-Pegol-and</p><p>7. Silverman LB, Blonquist TM, Hunt SK et al. Randomized study of pegaspargase (SS-PEG) and calaspargase pegol (SC-PEG) in pediatric patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma: results of the DFCI ALL consortium protocol 11-001. ASH Annual Meeting Abstracts. <i>Blood</i>. 2016; 128:175. https://ashpublications.org/blood/article/128/22/175/91239/Randomized-Study-of-Pegasparagase-SS-PEG-and?searchresult=1</p><p>8. Childhood acute lymphoblastic leukemia treatment. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2019 Oct 22. https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq</p><p>9. Adult acute lymphoblastic leukemia treatment. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2019 Feb 8. https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq</p><p>10. Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. <i>Pediatr Clin North Am</i>. 2015; 62:61-73. http://www.ncbi.nlm.nih.gov/pubmed/25435112?dopt=AbstractPlus</p><p>11. Boissel N, Sender LS. Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase. <i>J Adolesc Young Adult Oncol</i>. 2015; 4:118-28. http://www.ncbi.nlm.nih.gov/pubmed/26421220?dopt=AbstractPlus</p><p>41. Les Laboratoires Servier. Oncaspar<sup></sup> (pegasparase) summary of product characteristics. Suresnes, France; 2019 Nov 25.</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?</li>
</ul><h2>More about calaspargase pegol</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Calaspargase pegol-mknl Intravenous &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>